Dianthus Therapeutics Inc

In Stage 2 advancing, DNTH exhibits a Lockout Rally continuation with price extending above prior highs and tightly tracking rising EMAs. Medium-term bias remains bullish supported by Stage 2 structure and Bullish Pivot Point confirmation. Despite extreme overbought conditions, the Lockout Rally override justifies immediate participation in the breakout. We Buy Now to capture continuation, accepting elevated risk of a short-term pullback.

• ↑Initiation of Phase 3 EMERGE trial for Claseprubart in Myasthenia Gravis
• ↑Stock up 25.6% last month amid strong momentum factor
• ↓Negative earnings yield and weak profitability factors raise concerns